Skip to main content

Table 4 Pooled results of recurrence-free survival, progression-free survival and publication bias of comparing various BCG treatment schedules and doses

From: Optimal schedule of bacillus calmette-guerin for non-muscle-invasive bladder cancer: a meta-analysis of comparative studies

Measurement

n*

Case or case control

Heterogeneity

Pooled rate / HR

Begg’s test ( P)

Egger’s test ( P)

   

P

I 2(%)

(95% CI)

  

Recurrence-free survival

       

 Superficial bladder cancer

       

  Maintenance vs. Induction

9

521/536

0.150

12.0

0.516 (0.425-0.627)

0.602

0.353

  Low-dose vs. Standard-dose

7

998/1018

0.831

0.00

1.162 (1.051-1.285)

1.000

0.126

  BCG plus MMC vs. BCG

6

416/563

<0.001

79.1

0.726 (0.490-1.075)

0.452

0.334

  BCG plus MMC vs. MMC

3

213/225

0.297

17.7

0.854 (0.663-1.099)

0.296

0.132

  BCG plus Epirubicin vs. BCG

3

124/152

0.652

0.00

0.618 (0.384-0.993)

1.000

0.538

  BCG plus IFN-α2b vs. BCG

2

383/342

0.621

0.00

1.075 (0.859-1.345)

1.000

NA

 High-risk NMIBC

       

  Maintenance vs. Induction

5

353/362

0.272

22.4

0.515 (0.411-0.646)

0.086

0.032

  BCG plus MMC vs. BCG

3

314/298

<0.001

89.8

0.852 (0.449-1.617)

1.000

0.689

  BCG plus MMC vs. MMC

2

123/133

0.119

58.7

0.797 (0.477-1.330)

1.000

NA

  BCG plus Epirubicin vs. BCG

2

100/102

0.556

0.00

0.544 (0.302-0.980)

1.000

NA

Progression-free survival

       

 Superficial bladder cancer

       

  Maintenance vs. Induction

7

452/488

0.380

6.20

0.740 (0.572-0.957)

0.764

0.399

  Low-dose vs. Standard-dose

6

961/981

0.829

0.00

1.151 (0.853-1.554)

0.452

0.112

  BCG plus MMC vs. BCG

3

314/298

0.001

85.3

0.602 (0.181-1.999)

1.000

0.420

  BCG plus MMC vs. MMC

3

213/225

0.827

0.00

0.927 (0.482-1.784)

1.000

0.493

  BCG plus Epirubicin vs. BCG

2

100/102

0.980

0.00

0.513 (0.132-1.987)

1.000

NA

 High-risk NMIBC

       

  Maintenance vs. Induction

5

353/362

0.581

0.00

0.722 (0.548-0.951)

0.806

0.311

  BCG plus MMC vs. BCG

3

314/298

0.001

85.3

0.602 (0.181-1.999)

1.000

0.420

  BCG plus MMC vs. MMC

2

123/133

0.813

0.00

0.829 (0.387-1.773)

1.000

NA

  BCG plus Epirubicin vs. BCG

2

100/102

0.980

0.00

0.513 (0.132-1.987)

1.000

NA

  1. NA not applicable. Significant datas are emphasized in bold.
  2. * Number of included studies.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us